Key facts
- This page summarizes Jasmine Seror's Form 3 filing for CollPlant Biotechnologies Ltd (CLGN).
- 0 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 18 Mar 2026, 10:14.
Jasmine Seror - 18 Mar 2026 Form 3 Insider Report for CollPlant Biotechnologies Ltd (CLGN)
- Reporting relationship
- VP Product Development
- Issuer ticker
- CLGN
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/ Jasmine Seror
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Jasmine Seror filed Form 3 for CollPlant Biotechnologies Ltd (CLGN) on 18 Mar 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reporting Owners (1)
CIK 0002120241
Primary reporting owner
Seror Jasmine
- Relationship
- VP Product Development
- Address
- C/O COLLPLANT BIOTECHNOLOGIES LTD., 4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK, REHOVOT, ISRAEL
- Signature
- /s/ Jasmine Seror
- Signature date
- 18 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLGN
holding
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 12,000
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F2
CLGN
holding
Restricted Share Units
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 45,000
- Date
- 18 Mar 2026
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLGN
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 4,000
- Exercise price
- $4.02
- Footnotes
- F1, F4
CLGN
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 1,000
- Exercise price
- $4.02
- Footnotes
- F1, F4
CLGN
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 5,000
- Exercise price
- $6.39
- Footnotes
- F1, F4
CLGN
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 6,000
- Exercise price
- $6.39
- Footnotes
- F1, F4
CLGN
holding
Derivative
Options to Purchase Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 3,600
- Exercise price
- $6.39
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.
Footnote F2
Of the restricted share units reported herein, 5,250 units are vested, and the remaining 6,750 units vest in nine equal quarterly installments beginning June 8, 2026 and ending June 8, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
Footnote F3
The restricted shares shall vest over a period of 3 years: 33% shall vest on November 25, 2026, and the remaining 67% shall vest in eight equal quarterly installments thereafter.
Footnote F4
Fully vested and exercisable.